A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease

Jacob Laubach; Andrew J Yee; Jacalyn Rosenblatt; Jeffrey V Matous; Charles M. Farber; Thomas H. Openshaw; Rodrigo O. Maegawa; Michaela L. Tsai; Irene M. Ghobrial; Giada Bianchi; Bhupendra Rawal; Heidi Dipietro; Kristen Cummings; John Harran; Peter O'Gorman; Kathleen Scott; Kathleen Fitzpatrick; Jennifer Abovich; Hannah Baker; Alexandra Savell; Joshua Hansen; Paul Richardson

doi:10.1182/BLOOD-2018-99-116280

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease

Jacob Laubach
, Andrew J Yee
, Jacalyn Rosenblatt
, Jeffrey V Matous
, Charles M. Farber
, Thomas H. Openshaw
, Rodrigo O. Maegawa
, Michaela L. Tsai
, Irene M. Ghobrial
, Giada Bianchi
, Bhupendra Rawal
, Heidi Dipietro
, Kristen Cummings
, John Harran
, Peter O'Gorman
, Kathleen Scott
, Kathleen Fitzpatrick
, Jennifer Abovich
, Hannah Baker
, Alexandra Savell

Joshua Hansen, Paul Richardson

Harvard University
Beth Israel Deaconess Medical Center
Colorado Blood Cancer Institute, Denver, CO
Summit Medical Group, Florham Park, NJ
EMMC Cancer Center, Brewer, ME
Eastern Maine Medical Center
Virginia Piper Cancer Institute, Minneapolis,
Mater University Hospital, Dublin 7, Ireland
Cancer Trials Ireland, Dublin, Ireland

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	132
DOIs	https://doi.org/10.1182/BLOOD-2018-99-116280
State	Published - Nov 29 2018
Externally published	Yes

Disciplines

Medicine and Health Sciences
Internal Medicine

Access to Document

10.1182/BLOOD-2018-99-116280License: Unspecified

Cite this

Laubach, J., Yee, A. J., Rosenblatt, J., Matous, J. V., Farber, C. M., Openshaw, T. H., Maegawa, R. O., Tsai, M. L., Ghobrial, I. M., Bianchi, G., Rawal, B., Dipietro, H., Cummings, K., Harran, J., O'Gorman, P., Scott, K., Fitzpatrick, K., Abovich, J., Baker, H., ... Richardson, P. (2018). A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease. Blood, 132. https://doi.org/10.1182/BLOOD-2018-99-116280

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease. / Laubach, Jacob; Yee, Andrew J; Rosenblatt, Jacalyn et al.
In: Blood, Vol. 132, 29.11.2018.

Research output: Contribution to journal › Article › peer-review

Laubach, J, Yee, AJ, Rosenblatt, J, Matous, JV, Farber, CM, Openshaw, TH, Maegawa, RO, Tsai, ML, Ghobrial, IM, Bianchi, G, Rawal, B, Dipietro, H, Cummings, K, Harran, J, O'Gorman, P, Scott, K, Fitzpatrick, K, Abovich, J, Baker, H, Savell, A, Hansen, J & Richardson, P 2018, 'A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease', Blood, vol. 132. https://doi.org/10.1182/BLOOD-2018-99-116280

Laubach J, Yee AJ, Rosenblatt J, Matous JV, Farber CM, Openshaw TH et al. A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease. Blood. 2018 Nov 29;132. doi: 10.1182/BLOOD-2018-99-116280

@article{26b3c60f78824fe2959eae240d087953,

title = "A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease",

author = "Jacob Laubach and Yee, \{Andrew J\} and Jacalyn Rosenblatt and Matous, \{Jeffrey V\} and Farber, \{Charles M.\} and Openshaw, \{Thomas H.\} and Maegawa, \{Rodrigo O.\} and Tsai, \{Michaela L.\} and Ghobrial, \{Irene M.\} and Giada Bianchi and Bhupendra Rawal and Heidi Dipietro and Kristen Cummings and John Harran and Peter O'Gorman and Kathleen Scott and Kathleen Fitzpatrick and Jennifer Abovich and Hannah Baker and Alexandra Savell and Joshua Hansen and Paul Richardson",

note = "Jacob Laubach, Andrew J Yee, Jacalyn Rosenblatt, Jeffrey V Matous, Charles M. Farber, Thomas H. Openshaw, Rodrigo O. Maegawa, Michaela L. Tsai, Irene M.",

year = "2018",

month = nov,

day = "29",

doi = "10.1182/BLOOD-2018-99-116280",

language = "American English",

volume = "132",

journal = "Blood",

publisher = "American Society of Hematology",

}

TY - JOUR

T1 - A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease

AU - Laubach, Jacob

AU - Yee, Andrew J

AU - Rosenblatt, Jacalyn

AU - Matous, Jeffrey V

AU - Farber, Charles M.

AU - Openshaw, Thomas H.

AU - Maegawa, Rodrigo O.

AU - Tsai, Michaela L.

AU - Ghobrial, Irene M.

AU - Bianchi, Giada

AU - Rawal, Bhupendra

AU - Dipietro, Heidi

AU - Cummings, Kristen

AU - Harran, John

AU - O'Gorman, Peter

AU - Scott, Kathleen

AU - Fitzpatrick, Kathleen

AU - Abovich, Jennifer

AU - Baker, Hannah

AU - Savell, Alexandra

AU - Hansen, Joshua

AU - Richardson, Paul

N1 - Jacob Laubach, Andrew J Yee, Jacalyn Rosenblatt, Jeffrey V Matous, Charles M. Farber, Thomas H. Openshaw, Rodrigo O. Maegawa, Michaela L. Tsai, Irene M.

PY - 2018/11/29

Y1 - 2018/11/29

UR - https://ashpublications.org/blood/article/132/Supplement%201/1981/261942/A-Phase-II-Study-of-the-Efficacy-and-Safety-of

U2 - 10.1182/BLOOD-2018-99-116280

DO - 10.1182/BLOOD-2018-99-116280

M3 - Article

VL - 132

JO - Blood

JF - Blood

ER -

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease

Disciplines

Access to Document

Other files and links

Cite this